No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.5x · 10Y median 1.0x · 80th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:35:52.918Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Bioventus Inc. (BVS) stock was $13.15 as of Oct 6, 2026, 10:34 AM EDT, down 2.77% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +92.0% · 3-year avg +62.5%/yr · 5-year avg -0.8%/yr
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Medical - Devices · Durham, NC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
0.17
Revenue Est.
$149.51M
Last Quarter Results
EPS
$0.22
vs Estimate
$0.22
Revenue
$153.21M
vs Estimate
$155.44M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BVS | $890.55M | $13.14 | -2.77% | +91.99% | -0.81% | N/A | N/A |
| 2ABUS | $885.96M | $4.49 | -3.96% | +6.59% | +2.19% | +2.93% | vs BVS |
| 3CRVS | $864.45M | $10.28 | -4.28% | +49.09% | +17.88% | -4.26% | vs BVS |
| 4HSTM | $916.77M | $31.38 | -0.51% | +15.84% | +2.34% | +1.25% | vs BVS |
| 5MLTX | $926.95M | $11.02 | -3.16% | +34.80% | +2.81% | N/A | vs BVS |
| 6KURA | $928.59M | $10.46 | -1.51% | +10.92% | -10.73% | +5.98% | vs BVS |
3.90
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Consensus Rating
Based on 5 analysts
Average Price Target
$17.60
+33.9% upside
Low
$15.00
Current
$13.14
High
$19.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.15 | $0.15 | $0.15 | 3 |
| Quarter ending Dec 2026 | $0.23 | $0.24 | $0.24 | 3 |
| Quarter ending Mar 2027 | $0.15 | $0.15 | $0.15 | 1 |
| Quarter ending Jun 2027 | $0.24 | $0.24 | $0.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.77 | $0.78 | $0.79 | 4 |
| FY 2027 | $0.91 | $0.92 | $0.93 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $148.34M | $149.51M | $150.68M | 3 |
| Quarter ending Dec 2026 | $169.23M | $169.96M | $170.69M | 3 |
| Quarter ending Mar 2027 | $139.39M | $140.36M | $141.00M | 1 |
| Quarter ending Jun 2027 | $161.94M | $163.07M | $163.82M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $602.89M | $604.79M | $606.68M | 4 |
| FY 2027 | $638.11M | $645.58M | $653.04M | 4 |
